Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In The Treatment Of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)

Next Previous
Trial Profile

A Randomized Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In The Treatment Of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANT-3
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 15 Apr 2021 Results of post hoc pooled analysis from RADIANT-3 and RADIANT-4, published in the Cancer.
    • 12 Oct 2017 Results of pooled data assessing effectiveness of sunitinib and everolimus in patients with pancreatic neuroendocrine tumours from two trial (RADIANT-3 and A6181111 ), were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Sep 2016 Results of final overall survival and biomarker analysis published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top